S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Inflarx Stock Price, News & Analysis (NASDAQ:IFRX)

$2.33
-0.04 (-1.69 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$2.32
Now: $2.33
$2.41
50-Day Range
$2.24
MA: $2.67
$3.06
52-Week Range
$2.17
Now: $2.33
$53.10
Volume88,722 shs
Average Volume766,293 shs
Market Capitalization$60.50 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.51
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IFRX
CUSIPN/A
CIKN/A
Phone49-36-4150-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.64 per share

Profitability

Net Income$-35,210,000.00

Miscellaneous

Employees36
Market Cap$60.50 million
Next Earnings Date11/20/2019 (Estimated)
OptionableNot Optionable

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.


Inflarx (NASDAQ:IFRX) Frequently Asked Questions

What is Inflarx's stock symbol?

Inflarx trades on the NASDAQ under the ticker symbol "IFRX."

How were Inflarx's earnings last quarter?

Inflarx NV (NASDAQ:IFRX) issued its earnings results on Wednesday, August, 14th. The company reported ($0.66) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.11. View Inflarx's Earnings History.

When is Inflarx's next earnings date?

Inflarx is scheduled to release their next quarterly earnings announcement on Wednesday, November 20th 2019. View Earnings Estimates for Inflarx.

What price target have analysts set for IFRX?

9 brokerages have issued 1 year price objectives for Inflarx's stock. Their predictions range from $5.00 to $47.00. On average, they anticipate Inflarx's stock price to reach $17.43 in the next year. This suggests a possible upside of 648.0% from the stock's current price. View Analyst Price Targets for Inflarx.

What is the consensus analysts' recommendation for Inflarx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 2 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inflarx.

Has Inflarx been receiving favorable news coverage?

Media coverage about IFRX stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Inflarx earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Inflarx.

Are investors shorting Inflarx?

Inflarx saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,420,000 shares, a drop of 7.2% from the August 30th total of 1,530,000 shares. Based on an average daily trading volume, of 667,000 shares, the short-interest ratio is currently 2.1 days. Currently, 8.2% of the shares of the company are sold short. View Inflarx's Current Options Chain.

Who are some of Inflarx's key competitors?

What other stocks do shareholders of Inflarx own?

Who are Inflarx's key executives?

Inflarx's management team includes the folowing people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)
  • Mr. Arnd Christ, Chief Financial Officer (Age 53)
  • Mr. Jason M. Marks J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy

When did Inflarx IPO?

(IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Inflarx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Inflarx's stock price today?

One share of IFRX stock can currently be purchased for approximately $2.33.

How big of a company is Inflarx?

Inflarx has a market capitalization of $60.50 million. The company earns $-35,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Inflarx employs 36 workers across the globe.View Additional Information About Inflarx.

What is Inflarx's official website?

The official website for Inflarx is http://www.inflarx.de/.

How can I contact Inflarx?

Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180.


MarketBeat Community Rating for Inflarx (NASDAQ IFRX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel